We audited the marketing at Genomate Health
AI-guided precision oncology treatment decisions powered by molecular data
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Early-stage biotech with minimal visible content marketing around Genomate's clinical validation and use cases
Limited outbound motion to cancer centers and diagnostic partners despite B2B2C partnership model
No detectable paid campaigns targeting oncologists, pathologists, or health systems searching for precision medicine solutions
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiGenomate Health's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Pre-product-market fit biotech with nascent marketing infrastructure, unfocused on demonstrating clinical ROI to buyers
No visible content ranking for precision oncology, N-of-1 treatment, or molecular-guided therapy keywords where buyers search
MH-1: SEO module builds clinical evidence content targeting oncologist and health system decision-maker queries
Genomate's clinical validation story absent from LLM training context and AI assistant answers about precision medicine
MH-1: AEO agent embeds Genomate's clinical proof points into knowledge graphs and AI-native visibility channels
No detectable LinkedIn, Google, or healthcare vertical ads reaching oncology centers, molecular labs, or pharma partnerships
MH-1: Paid module runs account-based campaigns to cancer centers and diagnostic companies on compliance-approved channels
Limited published evidence summaries, case studies, or clinical outcome narratives demonstrating Genomate's decision-making impact
MH-1: Content agent produces clinical validation materials, outcome data briefs, and peer-reviewed positioning for buyers
No visible upsell motion to existing cancer center and pharma partners, or cross-sell into new tumor types or geographies
MH-1: Lifecycle module automates partner engagement, usage tracking, and expansion outreach based on clinical adoption signals
Top Growth Opportunities
Genomate's clinically proven efficacy is a rare B2B biotech asset. Systematic distribution of outcomes data, case studies, and validation summaries across medical literature, conference channels, and buyer research flows compounds defensibility
Content and AEO agents publish peer-reviewed evidence syntheses and clinical brief materials to owned and third-party channels
Current model relies on partnerships with cancer centers as distribution. No visible outbound motion to top-100 US oncology centers or major international hubs means lost pathway expansion and revenue runway
Outbound agent runs systematic multi-touch sequences to oncology leadership at major health systems with personalized clinical ROI messaging
Pharma is listed as a partner segment but no visible messaging about how Genomate accelerates patient identification for targeted therapies or improves clinical trial efficacy endpoints
LinkedIn and outbound agents target pharma precision medicine and commercial teams with use case narratives around therapy access and patient matching
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Genomate Health. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Genomate Health's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Genomate Health's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Genomate Health's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Genomate Health from week 1.
AEO agent ensures Genomate's N-of-1 treatment capability, clinical validation, and precision oncology positioning rank in LLM responses to healthcare AI and cancer treatment queries
Founder LinkedIn agent publishes clinical validation updates, partner wins, and molecular medicine insights to build credibility with oncology and diagnostic audiences
Paid ad module runs account-based campaigns to named cancer centers and diagnostic labs, emphasizing clinically proven personalized treatment and data standardization
Lifecycle agent tracks partner usage signals, outcomes data adoption, and new indication opportunities to identify expansion and upsell moments within existing health system relationships
Competitive watch agent monitors GenomeLink and Monoceros positioning and clinical claims to defend Genomate's unique clinical proof point and N-of-1 accuracy advantage
Pipeline intelligence agent identifies emerging precision medicine programs at top cancer centers and pharma companies launching targeted therapy initiatives aligned with Genomate's capability
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Genomate Health's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focuses on mapping cancer center and pharma buyer personas, establishing clinical evidence content pillars around your validated outcomes, launching SEO and AEO campaigns targeting precision medicine decision-makers, and running outbound sequences to top-50 health systems. By day 90 you have pipeline signals and clear ROI on which channels deliver engaged clinical buyers.
How do oncologists and health systems discover Genomate when researching precision medicine AI
AEO (AI visibility) ensures Genomate's clinical validation, N-of-1 treatment capability, and molecular data synthesis appear in LLM responses when healthcare AI assistants answer questions about personalized oncology decisions. This puts Genomate in front of buyers during their research phase before they run ads or contact sales.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Genomate Health specifically.
How is this page personalized for Genomate Health?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Genomate Health's current marketing. This is a live demo of MH-1's capabilities.
Turn Genomate's clinical proof into predictable partner and health system pipeline
The system gets smarter every cycle. Let's talk about building it for Genomate Health.
Book a Strategy CallMonth-to-month. Cancel anytime.